| Literature DB >> 29740639 |
Debra L Condon1, Danielle Beck2, Tawni Kenworthy-Heinige3, Karen Bratcher4, Meghan O'Leary5, Aliya Asghar6, Cyenthia Willis7, Marcus R Johnson5, Grant D Huang8.
Abstract
BACKGROUND: Recruitment into clinical trials remains a key determinant to study completion and success. While various strategies have been proposed, it is unclear how they apply across different populations, diseases, and/or study goals. The ability to effectively overcome challenges may require different approaches that more broadly focus on addressing obstacles among sites that cannot be overcome by individual studies.Entities:
Keywords: Clinical trials; Network; Recruitment; Sites; Veterans
Year: 2017 PMID: 29740639 PMCID: PMC5936861 DOI: 10.1016/j.conctc.2017.03.006
Source DB: PubMed Journal: Contemp Clin Trials Commun ISSN: 2451-8654
NODES Standardized Site Performance Report Categories.
| Site ID/Name |
| Total Participant Enrollment |
| Total Expected Enrollment |
| Percent Total Enrollment Reached |
| Total Enrollment Rank |
| Enrollment Over Past 6 Months |
| Percent Enrollment Over Past 6 Months |
| Enrollment Rank Over Past 6 Months |
| Enrolled in the Last Month |
| Last Enrollment Date |
Fig. 1Comparing participating sites monthly accrual of patients randomized, overall national ranking and interim ranking periods (e.g. 6-month rolling period), into site activation and expected to date targets. The top 20%–25% (based on study preference) meeting their respective site's targeted enrollment goal is represented in green, where sites in the bottom 20%–25% are represented in red.
Fig. 2Comparing participating sites expected to-date to observed to-date number of patients enrolled/randomized.
National six-month ranking of Actively enrolling CSP study teams supported by NODES.a.
| National Ranking | Number of actively enrolling CSP study teals at VAMCs with NODES (n) | Percentage of VAMCs with NODES in ranked category (n = 9) | Average NODES national rank for all CSP clinical trials | Average number of VAMCs actively enrolling in CSP clinical trials |
|---|---|---|---|---|
| Top 10% | 11 | 19% | 2 | 29 |
| Top 25% | 20 | 35% | 6 | 23 |
| Top 50% | 14 | 25% | 9 | 22 |
| Bottom 50% | 12 | 21 | 15 | 22 |
NODES six-month ranking period = December 2015–May 31, 2016.
NODES combined CSP clinical trials in active enrollment (N = 57).
Top 25% = > 10% ≤ 25%.
Top 50% = >25% ≤ 50%.
Bottom 50% = >50%.
The average cumulative NODE rank (1) is compared to the average number of active VAMCs conducting clinical trials within the ranking category.(2)